if the FDA provides enough detail in their response to the amphastar suit surrounding immunogenicity it would likely go some ways in lifting the overhang, since by extension a similar deficiency could apply to TEVA
Motion, I thought the TEVA overhang can never be lifted in a positive way for MNTA? Meaning TEVA either gets approval or the FDA keeps studing their application forever without giving a rejection.
At some point if it goes on long enough, MNTA will have enough cash that it won't matter.
Market Data 
Markets 
AI
